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Abstract
Background: The early detection of metastasis based on biomarkers in plasma may improve cancer prognosis and
guide treatment. The aim of this work was to characterize alterations in metabolites of the arginine pathway, energy
metabolism, and structural and signalling lipids in plasma in the early and late stages of murine breast cancer metastasis.
Methods: Mice were orthotopically inoculated with 4T1 metastatic breast cancer cells, and plasma was analysed along
the pulmonary metastasis progression using LC-MS/MS-based targeted metabolomics and lipidomics.
Results: Based on primary tumour growth and pulmonary metastases, 1–2weeks after 4T1 cancer cell inoculation was
defined as an early metastatic stage, and 3–4 weeks after 4T1 cancer cell inoculation was defined as a late metastatic
stage. Early metastasis was featured in plasma by a shift of L-arginine metabolism towards arginase (increased ornithine/
arginine ratio) and polyamine synthesis (increased putrescine). Late metastasis was reflected in plasma by further
progression of changes in the arginine pathway with an additional increase in asymmetric dimethylarginine plasma
concentration, as well as by a profound energy metabolism reprogramming towards glycolysis, an accelerated pentose
phosphate pathway and a concomitant decrease in tricarboxylic cycle rate (“Warburg effect”). The late but not the early
phase of metastasis was also characterized by a different lipid profile pattern in plasma, including a decrease in total
phosphatidylcholines, a decrease in diester-bound phospholipid fraction and an increase in lysophospholipids associated
with an increase in total sphingomyelins.
Conclusions: The early phase of metastasis in murine 4T1 metastatic breast cancer was associated with plasma
metabolome changes characteristic of arginase activation and polyamine synthesis. The late metastasis was reflected in
plasma not only by the alterations in arginine pathways but also by a shift towards glycolysis and the pentose pathway,
remodelling of structural lipids and activation of lipid signalling, all of which coincided with metastasis progression.
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Introduction
Although significant progress has been made in cancer re-
search during recent decades, breast cancer is still the most
frequently diagnosed tumour in women worldwide. The
survival rate of primary breast cancer is now close to 100%,
but it decreases to only 25% once distant metastasis has oc-
curred [1]. The prognosis and patient survival depend on
the cancer stage at the time of diagnosis. Therefore, dozens
of studies have been conducted with the aim of developing
new biomarkers that could be used for screening, diagnosis
and prognosis of cancer. Metabolomics, as the endpoint of
the ‘omics’ cascade, is focused on the investigation of the
global metabolites present in a biological specimen and is
considered representative of the phenotype [2]. Recent
metabolomic studies have expanded knowledge of the
mechanisms underlying cancer pathogenesis [3], and
several reports in the field of biomarker research have been
published using untargeted approaches that have enabled
the measurement of thousands of metabolites with the goal
of detecting previously unpredicted metabolite perturba-
tions. On the other hand, targeted studies, by quantitative
measurements of relatively smaller but pathway-oriented
metabolites, enable tracking the changes in a vast array of
metabolic enzymes, kinetics and end-products of a given
pathway known or suspected to be relevant to the disease
pathophysiology [4].
Several recent publications have demonstrated that tar-
geted metabolomics can prove useful not only for diagnosis
and monitoring response to treatment but also for finding
a relationship between clinicopathological characteristics of
breast cancer and various metabolites in blood, urine and
tissue specimens [5]. Depletion of the arginine plasma
pool, reprogramming of glucose metabolism and changes
in lipid metabolism reflecting either the increased arginine
and glucose use during cancer progression, hypoxic metab-
olism or restructuring of the cell membranes in tumours
[6] are important and pathophysiologically relevant
changes that accompany tumour development and may
influence cancer prognosis.
Arginine is a dibasic, semi-essential amino acid involved
in many biosynthetic pathways that can significantly influ-
ence carcinogenesis and tumour biology. It is metabolized
mainly by arginase (ARG) to urea and ornithine, which can
be further transformed into polyamines, and by nitric oxide
synthase (NOS) into nitric oxide (NO) and citrulline [7].
Polyamines are involved in cellular proliferation [8],
whereas metabolism of L-arginine by ARG was found to be
an important factor in controlling the immune response,
suppressing anti-tumour immune response and promoting
tumourigenesis [9, 10]. In particular, myeloid-derived sup-
pressor cells (MDSCs) consisting of precursors of granulo-
cytes, macrophages or dendritic cells that potently inhibit
the maturation and function of lymphocytes T, natural
killer and dendritic cells were reported to greatly expand in
human [11–13] and murine cancer [14], and their activity
was linked to increased arginine metabolism by ARG and
inducible nitric oxide synthase (iNOS) [15].
Metabolism reprogramming towards aerobic glycolysis—
the so-called ‘Warburg Effect’ [16]—represents an import-
ant adaptation of cancer cells to support cell survival,
tumour growth, tissue remodelling and cancer metastasis,
and it has been established as a new hallmark of cancer.
Finally, changes in lipid metabolism were shown to be
closely associated with cancer progression. Alterations in
lipid composition and abundance have been established as
a hallmark of cancer aggressiveness [17] that may strongly
influence both physical properties of membranes, such as
bilayer thickness, lipid packing density, membrane fluidity
or surface charge [18], and the signal transduction process
upon conversion into bioactive lipid mediators.
Given that changes in arginine metabolism [19–21],
energy metabolism reprogramming [21–23] and struc-
tural and signalling lipids [23–27] have been described
as potential biomarkers of cancer detection, progression
and prognosis, our goal was to find the earliest changes
in these pathways in plasma along the development of
breast cancer progression. We used a murine 4T1 car-
cinoma model because of its predisposition to spontan-
eous metastasis to the lung [28] using a low number of
inoculated cells, resulting in a relatively protracted time
course of pulmonary metastasis development, as ob-
served in our previous study [29–32]. We attempted to
perform targeted metabolomic analysis in blood plasma,
not locally in the tumour tissue, to evaluate measurable
systemic changes with potentially diagnostic significance
for the early phase of metastasis development.
We identified that the first systemically detectable meta-
bolic changes in plasma were linked with a shift in arginine
metabolism toward ARG, associated with early changes in
immune response as it coincided with infiltration of granulo-
cytes and extramedullary haematopoiesis. Later changes in
arginine metabolism also involved an increase in plasma
asymmetric dimethylarginine (ADMA) concentration,
suggesting endothelial dysfunction. In turn, the late phase of
metastasis was associated with plasma changes suggesting
energy metabolism reprogramming, modulation of structural
lipid content, and increased release of pro-inflammatory lipid
mediators, all of which coincided with tumour growth and
metastasis formation.
Methods
Murine model of metastatic breast cancer
Seven- to eight-week-old BALB/c female mice (obtained
from the Centre of Experimental Medicine, Medical
University of Bialystok, Poland) were orthotopically in-
oculated into the right mammary fat pad with 1 × 104 vi-
able mouse mammary adenocarcinoma 4T1 cells
(American Type Culture Collection, Manassas, VA,
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USA) cultured according to a previously described
protocol [29]. Healthy BALB/c mice injected with
Hanks’ balanced salt solution without 4T1 cells were
used as a control group. The overall number of mice in
the tumour-bearing group consisted of 40 mice (10 mice
per each group 1, 2, 3 and 4 weeks after cancer cell inocu-
lation). The control group consisted of 40 mice (10 mice
per each group 1, 2, 3 and 4 weeks after Hanks’ balanced
salt solution injection). At each time point, the groups of
10 tumour-bearing mice and 10 respective control mice
were injected with intraperitoneal (i.p.) administration of
heparin (25 IU/mouse) and anaesthetized by an i.p. injec-
tion of ketamine and xylazine (100mg ketamine/10mg
xylazine/kg body weight). Mice were killed, then their
blood was drawn by cardiac puncture, and their internal
organs were perfused in situ with Krebs buffer until
blood-free, dissected, weighed and collected for further
analysis.
All experimental procedures involving animals were
conducted according to the Guidelines for Animal Care
and Treatment of the European Communities and the
Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. All procedures were
approved by the Local Ethical Committee on Animal
Experiments at the Jagiellonian University (17/2016).
Blood count was measured by using an ABC Vet ana-
lyser (scil Animal Care Co., Gurnee, IL, USA), and
remaining blood was centrifuged at 3000 × g at 4 °C for
12 min, with plasma then kept for further analysis.
Tumour size was calculated by measuring the tumour
length (L) and width (W) using an electronic calliper
and expressed as tumour volume V = 0.52 × L × W2. In
order to determine pulmonary metastasis, representative
lung tissues from four mice were kept in buffered forma-
lin solution, and the macroscopic lesions were counted
in the lungs, as previously described [29]. For examin-
ation of liver haematopoiesis by histological analysis,
standard H&E staining of paraffin-embedded liver tissue
was used. Stained sections were examined and photo-
graphed at 100× magnification with an Olympus BX51
light microscope (Olympus Corporation, Tokyo, Japan).
Determination of metabolites from arginine metabolism,
energy metabolism and lipid content in plasma
In order to determine the concentration of selected metab-
olites from studied pathways, three LC-MS/MS targeted
metabolomics-based methods were applied. The arginine
metabolites were evaluated on the basis of LC-MS/MS
measurements using the AbsoluteIDQ p180 Kit (Biocrates
Life Sciences, Innsbruck, Austria) and a developed LC-MS/
MS targeted-metabolomic method, which was also used for
energy metabolite determination. The lipid profile was
evaluated using a flow injection analysis (FIA)-MS/MS
approach from the AbsoluteIDQ p180 Kit. The concentra-
tion of sphingosine-1-phosphate (S1P) was measured by
using an LC-MS/MS-based method, described below.
Energy metabolites (e.g., intermediates of glycolysis,
tricarboxylic acid cycle [TCA], pentose phosphate pathway
(PPP), amino acids and other intracellular metabolites
measured in plasma) were measured by employing an
LC-MS/MS technique on a QTRAP 5500 mass spectrom-
eter (SCIEX, Framingham, MA, USA) coupled to a UFLC
Nexera chromatograph (Shimadzu, Kyoto, Japan) using an
Acquity UPLC BEH C18 column, 1.7 μm, 3.0 × 100mm
(Waters, Milford, MA, USA) as an analytical column. Sam-
ples were analysed twice in positive and negative ionization
multiple reaction monitoring mode. The detailed method-
ology is included in Additional file 1.
Amino acids, biogenic amines and lipids in plasma were
measured using the commercially available AbsoluteIDQ
p180 kit, which allows for simultaneous quantification of
21 amino acids, 14 biogenic amines, 40 acylcarnitines, 90
glycerophospholipids, 15 sphingolipids and sum of hexoses.
The sample preparation and measurement were carried out
according to the kit manufacturer’s instructions. Briefly,
10 μl of standards, quality controls and plasma samples
were pipetted onto filter paper within each well plate of the
96-well plate provided by the kit manufacturer. The sam-
ples were dried under nitrogen, followed by application of
phenylisothiocyanate (MilliporeSigma, Burlington, MA,
USA), then they were dried again, and metabolites were
extracted from the filter paper using 5mM ammonium
acetate in methanol solution and diluted. Samples were
measured twice by LC-MS/MS (amino acid and biogenic
amines) and FIA-MS/MS (lipids and hexoses) using the
QTRAP 5500 mass spectrometer coupled to a UFLC
Nexera chromatograph. Quantification of metabolite
concentration and quality assessment were performed with
MetIQ software (Biocrates Life Sciences, Innsbruck,
Austria).
The concentration of S1P in plasma was determined by
using an LC-MS/MS technique with a TSQ Quantum mass
spectrometer system (Thermo Scientific, Waltham, MA,
USA) coupled to a UHPLC UltiMate 3000 (Dionex, Sunny-
vale, CA, USA). Chromatographic separation was achieved
with a Hypersil GOLD analytical column (1.9 μm, 2.1mm×
50mm; Thermo Scientific, Waltham, MA, USQ). The de-
tailed methodology is included in Additional file 1.
Statistical analysis
Statistical analysis was performed using STATISTICA 12
software (StatSoft Inc., Tulsa, OK, USA). All values are
expressed as mean ± SEM. The assessment of normality
and homogeneity of variances was performed using the
Shapiro-Wilk and Levene tests, respectively. To assess
the statistical significance, one-way analysis of variance
(ANOVA), Tukey’s posthoc test and a non-parametric
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Kruskal-Wallis ANOVA were performed. P values are
provided in the figure legends. For multivariate analysis,
data of all experiments were merged into a matrix table.
Partial least squares discriminant analysis (PLS-DA) and
heat map clustering of the data were performed using
web-based software (MetaboAnalyst 4.0) [33].
Results
Primary tumour growth and pulmonary metastasis
The primary tumour was barely palpable 1 week after
4T1 breast cancer cell inoculation, and reliable measure-
ment of primary tumour was possible starting from 2
weeks after 4T1 breast cancer cell inoculation. Two
weeks after 4T1 cancer cell inoculation, the mean
tumour weight and volume were 0.22 ± 0.08 g and 149.6
± 57.8 mm3, respectively, which represented c.a. 1.18% of
body weight, whereas 4 weeks after 4T1 cell inoculation,
the mean tumour weight and volume were 1.85 g ± 0.65
g and 1285 ± 415 mm3, respectively, which represented
10% of total body weight (Fig. 1a, b).
The pulmonary metastasis was not observed 1 week
after 4T1 breast cancer cell inoculation, and only a sin-
gle metastatic nodule in the lungs was observed 2 weeks
after cell inoculation. Three and four weeks after cancer
cell inoculation, metastatic lung nodules were present in
all tumour-bearing mice, reaching c.a. 5 and 12 meta-
static nodules, respectively (Fig. 1c).
No difference in spleen weight, an indirect parameter
of systemic inflammatory state [29], was found 1 week
after cancer cell inoculation, and a slight increase in
spleen weight was observed 2 weeks after 4T1 cell inocu-
lation (0.134 ± 0.028 g vs 0.07 ± 0.006 g in control mice),
whereas it was markedly increased 3 weeks (0.295 ±
0.057 g) and 4 weeks (0.52 ± 0.08 g) after cancer cell in-
oculation (Fig. 1d). These results were consistent with
the changes in blood count. The number of circulating
white blood cells was elevated from 2 weeks after 4T1
cell inoculation (12.8 ± 6.9 × 103/μl vs 4.1 ± 0.7 × 103/μl
in control mice) and reached 50.6 ± 15.89 × 103/μl and
189.9 ± 73.7 × 103/μl 3 and 4 weeks, respectively, after
cancer cell inoculation. Cancer-associated leucocytosis
was linked with a relative increase in number of granulo-
cytes and monocytes and a decreased number of lym-
phocytes, which was pronounced 3–4 weeks after cancer
induction (Table 1).
Altogether, based on primary tumour growth and pro-
gression of metastases to the lung and spleen weight, the
1–2-week period after 4T1 cancer cell inoculation was
defined as pre-metastatic and early metastatic stages
with a relatively small primary tumour, scarce pulmon-
ary metastasis and early stage of systemic inflammation,
whereas the 3–4 week period after 4T1 cancer cell
inoculation was considered the late metastatic stage with
accelerated primary tumour growth, advanced pulmon-
ary metastasis and severe systemic inflammation.
Alterations in arginine metabolism
The arginine plasma concentration tended to decrease in
early metastatic stage, but the difference reached statistical
significance 4 weeks after 4T1 cancer cell inoculation, sug-
gesting increased arginine use in tumour-bearing mice
(Fig. 2a). The plasma ornithine concentration increased
significantly 3 weeks after 4T1 cancer cell inoculation
(Fig. 2b). Overall, the ornithine-to-arginine ratio, compat-
ible with the activation of ARG that catalyses the catabol-
ism of arginine to ornithine and urea, was significantly
increased as early as 2 weeks after 4T1 cancer cell
inoculation (Fig. 2c). In the early phase of metastasis
ornithine-derived pro-proliferative polyamines—putres-
cine, spermidine and spermine (Fig. 2g–i)—also increased,
with most pronounced early changes in plasma concentra-
tion of putrescine (2 weeks after cancer cell inoculation).
The aforementioned changes in arginine metabolism were
even more pronounced in the late phase of metastasis.
In turn, the plasma concentration of citrulline, the
NOS-derived metabolite of arginine, did not change
Fig. 1 Primary tumour growth and development of pulmonary metastasis in a murine model of 4T1 metastatic breast cancer. Primary tumour
growth: weight (a) and volume (b) of primary tumour. Lung metastasis is expressed as the number of metastatic nodules (c). Empty bars
represent control animals, and black bars represent tumour-bearing mice. Occurrence of systemic inflammation is expressed as the increase of
spleen weight (d). Data are expressed as mean ± SEM (n = 10 for organ weight and n = 4 for lung metastatic nodules). Based on the normality of
distribution and variance homogeneity (F test), data were analysed by analysis of variance followed by Tukey’s post hoc test with statistical
significance set at *p < 0.05, **p < 0.01, ***p < 0.001
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significantly along breast cancer development (Fig. 2d).
The citrulline-to-arginine ratio increased only slightly
(Fig. 2e), but it was related to arginine decrease rather
than to citrulline increase and was visible only in the late
phase of metastasis (4 weeks after cancer cell inoculation).
Endogenous inhibitor of NOS—ADMA—substantially in-
creased (Fig. 2f) only in the late phase of metastasis (3–4
weeks after cancer cell inoculation), suggesting decreased
NOS activity in the late metastatic phase of breast cancer
progression.
In order to correlate the changes in arginine metabolisms
in plasma with the activation of extramedullary haemato-
poiesis, the latter reported previously to occur in this model
[28, 34, 35], we analysed liver samples by histology. As
shown in Fig. 3, small centres of extramedullary haemato-
poiesis with visible features of proliferation and initial
stages of hematopoietic cell differentiation were detected in
the liver as early as 1–2weeks after cancer cell inoculation
(Fig. 3). The size and number of hematopoietic centres in-
creased substantially in the late metastatic stage, 3–4 weeks
after cancer induction, with extensive proliferation and late
phases of differentiation. Moreover, in the late stage an
expansion of the number of leucocytes, among those also
immature ones, was seen in enlarged (widened) liver
sinusoids and conduit blood vessels within the liver (Fig. 3).
Reprogramming of energy metabolism
As shown in Fig. 4, the late phase of metastasis (3–4
weeks after 4T1 cell inoculation) but not the early
phase was associated with activation of glycolysis, pen-
tose phosphate pathway, glutaminolysis and diminution
of the TCA cycle, as evidenced by altered plasma con-
centrations of the respective metabolites. The concen-
trations of glycolytic intermediates measured in plasma
were elevated (e.g., concentration of hexose phosphate
and triose phosphate [dihydroxyacetone phosphate
{DHAP}] and D-glyceraldehyde-3-phosphate) were
increased by 50% and 200%, respectively, 3 weeks after
4T1 cell inoculation and by approximately 150% and
400%, respectively, 4 weeks after 4T1 cell inoculation as
compared with the control mice (Fig. 4a–c). Concomi-
tant with an increase in glycolytic intermediates, the
plasma levels of TCA products (e.g., fumarate and suc-
cinate) decreased 3–4 weeks after cancer cell inocula-
tion (Fig. 4d, e). Moreover, the increase of glutamine
(Gln) catabolism, evidenced as increased glutamate to
glutamine ratio (Glu/Gln) and acceleration of the PPP
(increased erythrose-4-phosphate [E-4-P] and
pentose-5-phosphate [Pentose-5-P])(was observed only
at the late and not at the early phase of metastasis
(Fig. 4f–h).
Alterations in structural and signalling lipids
The main changes in plasma phosphatidylcholine profile
were observed at the late phase of metastasis (3–4 weeks
after cancer cell inoculation) and included a decrease in
total phosphatidylcholine level (Total PC) with a simultan-
eous increase in the concentration of lysophosphatidylo-
cholines (LysoPC), the changes being compatible with the
increase in phospholipase A2 activity (Fig. 5a, b). The
profile of phosphatidylcholines was also altered, because
the fraction of phosphatidylcholines having two acyl chains
attached by ester linkage decreased, whereas lipids that
contain one acyl chain attached by an ether bound in-
creased (Fig. 5c, d). Additionally, 3–4 weeks after cancer
cell inoculation the unsaturation of acyl chains in phospha-
tidylcholines decreased, as evidenced by the reduction of
the ratio of polyunsaturated phosphatidylcholines to satu-
rated phosphatidylcholines by c.a. 20% (Fig. 5e) and short-
ening of the acyl-chain length in phosphatidylcholine
structures (Fig. 5f). The release of arachidonic acid from
phosphatidylcholines was augmented at the late phase but
not the early phase of metastasis, as evidenced by the in-
crease in the ratio of various LysoPC to
Table 1 Circulating white blood cell analysisa
1 week 2 weeks 3 weeks 4 weeks
Control 4T1 Control 4T1 Control 4T1 Control 4T1
WBCb 4.5 ± 1.1 4.3 ± 1.5 4.1 ± 0.7 12.8 ± 6.9 4.8 ± 0.8 50.6 ± 15.9 4.4 ± 1.1 189.0 ± 73.7
GRAc 1.1 ± 0.2 1.4 ± 0.5 1.0 ± 0.3 8.1 ± 5.5 1.0 ± 0.2 35.7 ± 12.7 0.9 ± 0.3 143.6 ± 55.2
GRA%d 23.6 ± 7.2 31.5 ± 6.8 21.1 ± 4.0 57.8 ± 11.6 18.6 ± 1.6 69.7 ± 4.9 18.4 ± 2.9 75.0 ± 3.6
LYMc 3.3 ± 1.0 2.7 ± 1.0 3.0 ± 0.5 4.1 ± 1.2 3.7 ± 0.7 11.5 ± 2.8 3.3 ± 0.8 31.5 ± 11.9
LYM%d 71.8 ± 8.9 63.5 ± 7.4 75.1 ± 4.5 36.9 ± 11.2 77.6 ± 1.6 23.5 ± 3.8 77.6 ± 3.0 17.2 ± 2.4
EOSc 3.6 ± 1.4 5.0 ± 1.1 3.3 ± 1.1 11.4 ± 4.4 3.5 ± 0.6 9.2 ± 3.4 3.0 ± 1.7 66.5 ± 13.7
MONc 0.14 ± 0.1 0.2 ± 0.1 0.1 ± 0.02 0.6 ± 0.3 0.1 ± 0.03 3.4 ± 1.4 0.1 ± 0.05 14.9 ± 8.3
MON%d 4.6 ± 1.9 4.8 ± 1 3.8 ± 0.5 5.3 ± 1.1 3.8 ± 0.4 6.8 ± 1.8 3.9 ± 0.4 7.8 ± 1.8
Abbreviations: EOS Eosinophils, GRA Granulocytes, LYM Lymphocytes, MON Monocytes, WBC White blood cells
aWhole blood was collected by cardiac puncture at the indicated time after orthotopic introduction of tumour cells, as described in the Methods section of text
bTotal number of WBC per microliter of blood in thousands ± SEM
cNumber of cells per microliter of blood in thousands ± SEM
dThe percentage of total WBC ± SEM
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Fig. 2 Shunts of arginine metabolism into arginase pathway, synthesis of polyamines and asymmetric dimethylarginine (ADMA) detected in
plasma in murine model of 4T1 metastatic breast cancer. Decrease in arginine plasma pool (a), increase in ornithine concentration (b) and
ornithine-to-arginine ratio (c) in tumour-bearing mice, suggesting an increase in arginase activity. Lack of changes in citrulline plasma
concentration (d), slight increased citrulline-to-arginine ratio (e) and increase in concentration of asymmetric dimethylarginine (f) in
tumour-bearing mice, suggesting impaired nitric oxide synthase (NOS) activity. Increased plasma concentrations of putrescine (g),
spermidine (h) and spermine (i) in tumour-bearing mice suggesting increased polyamine synthesis. An overview of 4T1 breast cancer
cell-related alterations in L-arginine metabolism (j). Empty bars represent control animals, and black bars represent tumour-bearing
mice. Data are expressed as mean ± SEM (n = 10). The data were analysed with either analysis of variance (ANOVA) followed by Tukey’s
post hoc test (arginine, ornithine/arginine, putrescine) or non-parametric Kruskal-Wallis ANOVA (ornithine, citrulline, citrulline/ornithine,
ADMA, spermidine, spermine), depending on the normality of distribution and variance homogeneity (F test) with statistical significance
set at *p < 0.05, **p < 0.01, ***p < 0.001. ARG Arginase, ODC Ornithine decarboxylase, Spd Syn Spermidine synthase, Spm Syn
Spermine synthase
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phosphatidylcholines indicating release of 20:4 fatty acid
arachidonate (LysoPC 16:0/PC 36:4; LysoPC 16:1/ PC 36:1;
LysoPC 18:0/ PC 38:4; LysoPC 18:1/PC 38:5; LysoPC18:2/
PC 38:6) and decrease of LysoPC containing arachidonic
acid (LysoPC 20:4) (Fig. 5g, h).
The decrease in PC fraction was related to a
concomitant increase in sphingomyelin (SM) fraction
in the plasma phospholipid profile, also visible to some
extent in the early phase of metastasis. The SM content
was elevated by c.a. 15% and 30% at 2 and 4 weeks,
respectively, after cancer cell inoculation (Fig. 5i). The
changes in concentration of S1P, a SM-derived
signalling molecule, displayed a biphasic course, being
increased at the early phase of metastasis (2 weeks after
cancer cell inoculation) and then significantly reduced
in the late phase of metastasis (Fig. 5j).
Partial least squares discriminant analysis
In order to confirm the significance of changes in me-
tabolites of the arginine pathway, energy metabolism,
and structural and signalling lipids in plasma during
the development of metastatic 4T1 breast cancer in
mice, a multivariate statistical analysis was performed.
An orthogonal PLS-DA model (Fig. 6a) that was built
based on measured metabolites demonstrated robust
group separation between cancer-bearing mice and
control mice with R2 and Q2 of 0.712 and 0.45, re-
spectively. Additionally, by employing sparse PLS-DA,
also differentiation between control mice and mice at 1, 2,
3 and 4 weeks after cancer cell inoculation can be seen;
yet, the R2 (0.577) and Q2 (0.041) values, calculated based
on a ten-fold cross-validation approach were low, prob-
ably due to the small number of animals in each group
(n = 40 for control and n = 10 for tumour-bearing mice 1,
2, 3 and 4 weeks after 4T1 cancer cell inoculation)
(Fig. 6b). Hierarchical cluster analysis for the measured
metabolites was described by the Ward algorithm and ar-
ranged according to similarity in metabolite profile. As
shown in Fig. 6c, a heat map of 25 top metabolites dem-
onstrated clear-cut separation between two main clusters:
a late metastatic group (3 and 4 weeks after 4T1 cancer
cell inoculation) and a control and early metastatic group
(1–2 weeks after 4T1 cancer cell inoculation) together. In
fact, the biggest difference can be seen between the con-
trol and late metastatic groups based on changes in argin-
ine, energy pathways and lipids. The separation between
the control and early metastatic groups, although visible,
was weaker and was linked to changes in arginine metab-
olism and some lipids.
Discussion
In the present work, taking advantage of targeted
LC-MS-based metabolomics and lipidomics focused on
arginine metabolism, energy metabolism and structural
and signalling lipids, we demonstrated that in 4T1 meta-
static breast cancer in mice, the early phase of metastasis
was mirrored in plasma by changes in arginine metabolism
characteristics for ARG activation and polyamine synthe-
sis. The late metastasis, apart from alterations in arginine
pathways, was characterized by a shift of energy metabol-
ism towards glycolysis and PPP, remodelling of structural
lipids and activation of lipid signalling (Fig. 7). Altogether,
we detected changes in the plasma metabolome featuring
an early phase of metastasis compatible with the shift in
arginine metabolism towards ARG that could constitute
an early plasma biomarker of cancer progression and me-
tastasis and an early target of metastasis treatment [36]. In
Fig. 3 Extensive extramedullary haematopoiesis in the liver during
cancer progression in a murine model of 4T1 metastatic breast cancer.
Normal liver in the control group (a). The progressive increase in the area
of hematopoietic centres in the liver during 4T1 metastatic breast cancer
progression (b–e). Small island of extramedullary haematopoiesis in the
vicinity of blood vessel walls (first week after 4T1 cell inoculation) (b);
increase of hematopoietic centre size near blood vessels and formation
of new foci in the liver parenchyma, visible features of proliferation and
initial stages of cell differentiation (second week after 4T1 cell inoculation)
(c); formation of numerous hematopoietic centres in liver tissue, both in
the vicinity of vascular walls and in liver parenchyma, visible cells in
different and late stages of differentiation (third week after 4T1 cell
inoculation) (d); further increase in number and size of hematopoietic
centres, visible variation in the type of produced leucocytes, in the
winded sinusoids, numerous leucocytes, among which also immature
leucocytes are visible (fourth week after 4T1 cell inoculstion) (e)
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turn, a number of other changes that have been identified
in energy metabolism and lipids may provide biomarkers
of an advanced stage of metastatic cancer [37].
The salient finding of this study was the early detec-
tion of a significant change in arginine metabolism that
was detected in plasma even before the first breast can-
cer metastasis to the lung and involved acceleration of
arginine catabolic rate as well as an increased polyamine
synthesis. Acceleration of ARG activity seemed to coin-
cide with the increased production of leukocytes
(Table 1), which were identified by Donkor et al. [38] in
a 4T1 model as arginine-dependent MDSCs. These
MDSCs’ immunosuppressive activity, related to in-
creased arginine metabolism via ARG and iNOS [15,
39], was shown to accompany tumour progression and
metastasis [40] and caused profound perturbation in
myelopoiesis, including extramedullary myelopoiesis to
meet the increased demand for myeloid cell proliferation
[41, 42]. Indeed, we observed an increase in the number
and size of hematopoietic centres in the liver (Fig. 3),
which supports active MDSC formation. Moreover, ARG
activation resulted in the increased synthesis of ornithine-
derived polyamines (Fig. 2g–i), which could additionally
stimulate disease progression by participating in cancer
cell proliferation [43] and tumour vascularization [44].
These changes were followed by alterations of ADMA
synthesis regulating NOS-dependent function in the
late phase of metastasis (Fig. 2f ). The formation of a
pre-metastatic niche is associated with early local pul-
monary NO deficiency that contributes to lung metas-
tasis [29–31] and systemic endothelial dysfunction
linked to systemic inflammation [45, 46]. It could well
be that ADMA-mediated impairment of NO produc-
tion may also have a pathophysiological role in the de-
velopment of systemic endothelial dysfunction
associated with advanced cancer.
Altogether, we claim that induction of ARG activity
detected in plasma in the early phase of metastasis
Fig. 4 Reprogramming of energy metabolism associated with cancer growth detected in plasma in a murine model of 4T1 metastatic breast
cancer. Increase in glycolytic rate, evidenced as an increase of hexose phosphate (a), fructose 1,6-bisphosphate (b), glyceraldehyde 3-phosphate
and dihydroxyacetone phosphate (c) concentrations measured in plasma, and a decrease of tricarboxylic acid cycle intermediate plasma
concentrations of succinate (d) and fumarate (e). Increase of glutamine catabolism evidenced as an increase in glutamate-to-glutamine
ratio (f) and acceleration of pentose phosphate pathway increase of erythrose 4-phosphate (g) and pentose phosphate concentrations (h).
A simplified overview of 4T1 breast cancer-induced changes in energy metabolism (i). Empty bars represent control animals, and black
bars represent tumour-bearing mice. Data are expressed as mean ± SEM (n = 10). The data were analysed with either analysis of variance
(ANOVA) followed by Tukey’s post hoc test (GADP_DHAP, fumarate, Gln/Glu) or a non-parametric Kruskal-Wallis ANOVA (Hexose-P, fructose
1,6-bisphosphate, succinate, E4P, Pentose-5P), depending on the normality of distribution and variance homogeneity (F test), with
statistical significance set at *p < 0.05, **p < 0.01, ***p < 0.001
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formation in 4T1 metastatic breast cancer in mice
contributes to metastasis progression. Indeed, it was
shown that the ARG inhibitor Nω-hydroxy-nor-L-argi-
nine reduced the inhibitory effect of MDSCs on
T-cell proliferation and reduced the number and size
of pulmonary metastasis [36]. Moreover, pegylated
derivatives of ARG inhibited tumour cell growth by
depletion of the arginine pool for polyamine synthesis
[47]. Novel compounds reducing arginine activity are
under investigation in humans: pegylated Arg1
AEB1102 in phase I/II study (NCT02488044) and
ARG inhibitor CB-1158 in a phase I clinical trial
(NCT02903914). Accordingly, changes in arginine me-
tabolism detected in the plasma can represent an
important and pathophysiologically relevant marker of
early phases of cancer and metastasis.
Surprisingly, in contrast to changes in arginine metabol-
ism that occurred in an early phase of metastasis, changes
in energy metabolism (Fig. 4) were observed in the late
phase of metastasis only and involved the switch of energy
production to glycolysis (the ‘Warburg effect’), increased
catabolism of Gln and accelerated PPP, all of which are
characteristic of cancer development [48]. It might well be
that the plasma glycolysis metabolome reflected not only
a direct leakage of metabolites from tumour being big
enough to induce changes in plasma metabolome, but also
a significant recruitment and activation of immune cells
in blood that also depends on glycolysis [49].
Fig. 5 Changes in lipid fractions detected in plasma in a murine model of 4T1 metastatic breast cancer indicating alterations in membrane
structure and lipid signalling. Increase of phospholipase A2 activity observed as a decrease in total plasma phosphatidylcholines (a) and an
increase of lysophosphatidylocholines (b). Changes in diacyl chain phosphatidylcholine fractions: decrease in diester-bound phosphatidylcholines
(c) and increase in ester-ether-bound (plasmalogen) fraction (d). Decrease in unsaturation of plasma lipids, measured as a ratio of polyunsaturated
lipids to saturated lipids (e). Increased short-chain phospholipid fraction (f). Increase in arachidonic acid release, measured indirectly as a sum of
specific ratios of most abundant lysophosphatidylocholines to phosphatidylcholines indicating release of arachidonic acid (LysoPC 16:0/PC 36:4,
LysoPC 16:1/PC 36:1, LysoPC 18:0/ PC 38:4, LysoPC 18:1/PC 38:5, LysoPC18:2/PC 38:6) (g) and decrease of lysophosphatidylocholine-containing
arachidonic acid (h). Increase of total amount of sphingomyelins (SMs) in 4T1 tumour-bearing mice (i). Changes in the plasma concentration of
sphingosine-1-phosphate (j). Empty bars represent control animals, and black bars represent tumour-bearing mice. Data are expressed as mean ±
SEM (n = 10). The data were analysed with either analysis of variance (ANOVA) followed by Tukey’s post hoc test (Total PC ae/Total PC, Lyso PC a
20:4/Total Lyso PC, Total SM/Total PC) or a non-parametric Kruskal-Wallis ANOVA (Total PC, Total Lyso PC/Total PC, Total PC aa/Total PC, PUFA
(PC)/SFA (PC), Short AcPC/Total PC, AA release, S-1-P), depending on the normality of distribution and variance homogeneity (F test), with
statistical significance set at *p < 0.05, **p < 0.01, ***p < 0.001
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In the present work, we also identified a number of
changes in lipid profile that all occurred in the late
phases of cancer and metastasis (Fig. 5) and involved
alterations related to structural and signalling lipid
composition in blood plasma, which indicated remodel-
ling of biological membranes and activation of
lipid-dependent signals. In fact, changes in structural
lipids such as increased formation of SM-rich lipids at
the expense of PCs (Fig. 5a, i), reduction of lipid unsat-
uration (Fig. 5d), increased amount of ether lipids
(Fig. 5f ) and higher content of lipids with short acyl
chains (Fig. 5f ) may all contribute to alteration in
membranes’ nanomechanical properties, to increased
cancer aggressiveness [50, 51] and to increased vascular
permeability [18]. In turn, increased release of many
pro-proliferative and anti-apoptotic lipids, such as
lysophosphatidic acid, derived from LysoPC (Fig. 5b) or
platelet-activating factor, derived from ether phospho-
lipids (Fig. 5d), can contribute to proliferation, survival,
migration, vesicle trafficking and inflammation,
tumourigenesis or metastasis through inter- and
intra-cellular signalling [51–54], Interestingly, plasma-
logens, also derived from ether lipids augmented at late
metastatic stage, known to be important reservoirs of
arachidonate, can activate Akt and extracellular
signal-regulated kinase survival signalling, which pro-
tects against apoptosis [55]. The altered arachidonic
acid metabolism reported here (Fig. 5g, h) is also a
Fig. 6 Changes of the measured metabolites in plasma of control and tumour-bearing mice. Orthogonal partial least squares discriminant
analysis score plot of the qualified metabolites in plasma of control and tumour-bearing mice showing classes separation according to
their metabolic signature (a). Sparse partial least squares discriminant analysis score plot to differentiate control and tumour-bearing mice
1–4 weeks after cancer cell inoculation (b). Heat map and hierarchical clustering of discriminant metabolites in control and tumour-
bearing mice 1–4 weeks after cancer cell inoculation shows differing concentrations of 25 top statistically significant metabolites in
studied groups. Each column represents the average metabolite concentration of ten mice for the experimental condition (c)
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common feature of malignancies (see review [56]). In
turn, the metabolism of SM leads to formation of cera-
mides and S1P, which are related to cancer cell prolifer-
ation and apoptosis regulation [57, 58]. There is good
evidence supporting the hypothesis that S1P is involved
in mesenchymal transformation, increased invasiveness,
glucose metabolism or neovascularization [59]. Add-
itionally, S1P is known as a regulator of endothelial bar-
rier function [60] and therefore may influence the
extravasation of cancer cells. In our study, transiently
increased plasma S1P level (Fig. 5j) could contribute to
early changes in endothelial permeability required for
metastases formation.
In the present work, on the basis of multivariate statis-
tical analysis, we confirmed that the plasma profile of ar-
ginine metabolism, energy metabolism and lipids was
clearly distinct for 4T1 breast cancer-bearing mice and
control mice, as well as for the late metastatic group (3
and 4 weeks after cancer cell inoculation) and the early
metastatic and control groups (1–2 weeks after cancer
cell inoculation), taken together. The early metastatic
group was also to some extent differentiated from the
control group on the basis of changes in arginine
metabolism and some lipids. Our multivariate statistical
analysis was performed based on ten animals per experi-
mental groups. Obviously, this approach was sufficient
for the detection of meaningful changes in targeted
analysis of selected metabolites, but it was not sufficient
to achieve high statistical power in multivariate statis-
tical analysis.
Conclusions
In the present work, we demonstrated that progression of
4T1 metastatic breast cancer in mice was linked to distinct
metabolomic changes in plasma in the early and late phases
of metastasis. The early phase of metastasis was featured
by an increase in ARG activity and polyamine synthesis that
can be associated with ARG-dependent immunosuppres-
sion and polyamine-dependent cellular proliferation, re-
spectively. The late phase of metastasis was reflected in
plasma by alterations in arginine pathways involving not
only ARG activity and polyamine synthesis but also
increased ADMA synthesis that can be linked with an im-
pairment of endothelial function. However, the late phase
of metastasis but not the early phase was featured in plasma
by reprogramming of energy metabolism toward glycolysis
and the pentose phosphate pathway at the expanse of the
TCA, as well as by remodelling of structural and signalling
lipids, all of which coincided with metastasis progression.
Altogether, the ARG pathway constitutes an early plasma
biomarker of cancer and metastasis and an important
target for therapy, whereas metabolism reprogramming to-
wards glycolysis and changes in signalling and structural
lipids, if detected in plasma, constitute biomarkers for
advanced cancer and the late phase of metastasis.
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Fig. 7 Scheme of metabolic network changes in the early and late stages of metastatic 4T1 breast cancer in mice. Early phase of metastasis is
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is characterized by energy metabolism reprogramming (‘Warburg effect’) and alterations in structural and signalling lipid profile in murine plasma
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